Control of lymphocyte infiltration of lung tumors in mice by host's genes: mapping of four Lynf (lymphocyte infiltration) loci.
Tumor infiltration by lymphocytes is essential for cell-mediated immune elimination of tumors in experimental systems and in immunotherapy of cancer. Presence of lymphocytes in several human cancers has been associated with a better prognosis. We present evidence that individual propensity to tumor infiltration is genetically controlled. Infiltrating lymphocytes are present in 50% of lung tumors in O20/A mice, but in only 10% of lung tumors in OcB-9/Dem mice. This difference has been consistent in experiments conducted over 8 years in two different animal facilities. To test whether this strain difference is controlled genetically, we analyzed the presence of infiltrating lymphocytes in N-ethyl-N-nitroso-urea (ENU) induced lung tumors in (O20 x OcB-9) F(2) hybrids. We mapped four genetic loci, Lynf1 (Lymphocyte infiltration 1), Lynf2, Lynf3, and Lynf4 that significantly modify the presence and intensity of intra-tumoral infiltrates containing CD4(+) and CD8(+) T lymphocytes. These loci appear to be distinct from the genes encoding the molecules that are presently implicated in lymphocyte infiltration. Our findings open a novel approach for the assessment of individual propensity for tumor infiltration by genotyping the genes of the host that influence this process using DNA from any normal tissue. Such prediction of probability of tumor infiltration in individual cancer patients could help considerably to assess their prognosis and to decide about the application and the type of immunotherapy.
Kakarlapudi
Neelima
N
Department of Molecular and Cellular Biology, Roswell Park Cancer Institute, Elm and Carlton Streets, Buffalo, NY 14263, USA.
Vernooy
Juanita H J
JH
Quan
Lei
L
Fijneman
Remond J A
RJ
Demant
Peter
P
D000818:Animals; D015496:CD4-Positive T-Lymphocytes / Q000276:immunology; D018414:CD8-Positive T-Lymphocytes / Q000276:immunology; D002273:Carcinogens / Q000633:toxicity; D005038:Ethylnitrosourea / Q000633:toxicity; D005838:Genotype; D007150:Immunohistochemistry; D008175:Lung Neoplasms / Q000139:chemically induced / Q000235:genetics* / Q000276:immunology*; D016246:Lymphocytes, Tumor-Infiltrating / Q000502:physiology*; D051379:Mice; D008822:Mice, Transgenic; D009374:Neoplasms, Experimental / Q000139:chemically induced / Q000235:genetics / Q000276:immunology; D018807:Polymorphism, Single-Stranded Conformational
D002273:Carcinogens; D005038:Ethylnitrosourea
Mamm Genome. 1996 Jan;7(1):55-8
8903730
Curr Opin Immunol. 2006 Apr;18(2):214-9
16464567
Science. 2006 Sep 29;313(5795):1960-4
17008531
Cancer Res. 2003 Jan 1;63(1):125-31
12517788
Cancer Res. 1998 Oct 15;58(20):4673-81
9788621
J Exp Med. 1997 Jul 21;186(2):229-38
9221752
Cancer Immunol Immunother. 2003 Jul;52(7):423-8
12695859
FASEB J. 1992 Jul;6(10):2826-35
1634045
Exp Lung Res. 2005 Jun;31(5):513-25
16019985
Immunogenetics. 1986;24(6):416-22
3793154
Science. 1996 Apr 5;272(5258):60-6
8600538
Cancer. 1996 Apr 1;77(7):1303-10
8608507
Nat Genet. 1996 Dec;14(4):465-7
8944028
Nat Rev Immunol. 2003 Nov;3(11):867-78
14668803
Cancer Res. 2004 May 15;64(10):3458-64
15150098
Int J Cancer. 2005 Apr 10;114(3):394-9
15551356
Nature. 2001 Jun 28;411(6841):1058-64
11429607
Proc Natl Acad Sci U S A. 2005 Dec 20;102(51):18538-43
16344461
Cancer Invest. 2005;23(5):413-9
16193641
Semin Cancer Biol. 2006 Apr;16(2):115-23
16376102
Cancer Res. 2005 Oct 15;65(20):9113-6
16230363
Exp Lung Res. 2001 Apr-May;27(3):185-96
11293323
Nat Genet. 1995 Nov;11(3):241-7
7581446
Am J Respir Cell Mol Biol. 2002 Jan;26(1):152-9
11751215
J Natl Cancer Inst. 2001 Oct 3;93(19):1484-91
11584065
Nat Rev Cancer. 2006 Jan;6(1):24-37
16397525
Cancer Immunol Immunother. 2003 Nov;52(11):670-9
12920482
Cancer Immunol Immunother. 2005 Nov;54(11):1137-42
15877228
Immunol Rev. 1999 Jun;169:263-72
10450523
N Engl J Med. 2004 Apr 1;350(14):1461-3
15070799
Exp Lung Res. 1998 Jul-Aug;24(4):419-36
9659575